الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 117 |  |  |
| | | from | 117 | | |
Abstract
”Acute myeloid leukemia (AML) is an uncontrolled clonal proliferation of myeloid precursors resulting in collection of leukemic blasts within bone marrow (BM), peripheral blood and other tissues.AML is rapidly lethal if untreated. With intensive treatment, 60 to 80 % of younger adults achieve a complete remission (CR).Allo-HSCT is a potentially curative therapy for AML cases. But, a human leukocyte antigen (HLA)-identical sibling is available for 25–35% of AML cases. For those who lack a full matched sibling donor (MSD), other stem cell sources are available including an unrelated donor, or a HLA-mismatched family donor (Haplo).The aim of work: Detection Different transplant related toxicity and Comparing outcome of matched sibling donor versus haplo-identical as regard leukemia free survival (LFS) and overall survival (OS) Research Plan: This retrospective study was conducted on 40 patients adult AML (non-APL) 50% of them underwent BMT from matched doner and 50% from haploidentical donor recruited from Naser cancer institute, Air Force specialized hospital in period from May 2016 to May 2021 and patients received chemotherapy at Oncology center Mansoura University then referred for BMT.